Breast Cancer Research and Treatment

, Volume 95, Issue 3, pp 199–209 | Cite as

Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review

  • B. Gerber
  • C. Scholz
  • T. Reimer
  • V. Briese
  • W. Janni
Review

Summary

Complementary and alternative medicine (CAM) is becoming increasingly popular, particularly among patients with breast cancer. We have done a systematic review of studies published between 1995 and February 2005, identified through a comprehensive search. CAM encompasses a wide range of treatment modalities, including dietary and vitamin supplements, mind-body approaches, acupuncture, and herbal medicines. The objectives of CAM treatments are diverse: reduction of therapy-associated toxicity, improvement of cancer-related symptoms, fostering of the immune system and even direct anticancer effects. Clinical trials have generated few or no data on the efficacy of CAM, whether regarding disease recurrence, survival, overall quality of life or safety. Some CAM methods may even have adverse effects or reduce the efficacy of conventional treatment. The primary justification for CAM is based on empirical evidence, case studies, and hypothetical physiological effects. We conclude that␣available data on CAM modalities in the treatment of early-stage breast cancer does not support their application.

Keywords

acupuncture breast cancer herbals mistletoe phytoestrogens proteolytic enzymes psychological therapies soy trace elements vitamins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    NCAM. http://www.nccam.nih.gov. 2004 Google Scholar
  2. 2.
    Engel LW, Straus SE, Development of therapeutics: opportunities within complementary, alternative medicineNat Rev Drug Discov 1: 229–237, 2002CrossRefPubMedGoogle Scholar
  3. 3.
    Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL: Unconventional medicine in the United States. Prevalence, costs, patterns of use. N Engl J Med 328: 246–252, 1993Google Scholar
  4. 4.
    Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F, Zheng W, Use of complementary, alternative medicine by Chinese women with breast cancerBreast Cancer Res Treat 85: 263–270, 2004CrossRefPubMedGoogle Scholar
  5. 5.
    Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA, An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies J Clin Oncol 22: 671–677, 2004CrossRefPubMedGoogle Scholar
  6. 6.
    Adler SR, Complementary and alternative medicine use among women with breast cancerMed Anthropol Q 13: 214–222, 1999CrossRefPubMedGoogle Scholar
  7. 7.
    Metz JM, Jones H, Devine P, Hahn S, Glatstein E, Cancer patients use unconventional medical therapies far more frequently than standard history, physical examination suggest Cancer J 7: 149–154, 2001PubMedGoogle Scholar
  8. 8.
    Oxford Centre for Evidence-based Medicine Levels of Evidence. Levels of Evidence and Grades of Recommendation. 2004. 13–4–2004 Google Scholar
  9. 9.
    NCI. http://www.cancer.gov/. Breast Cancer Res Treat. 2004 Google Scholar
  10. 10.
    Robinson KA, Dickersin K, Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMedInt J Epidemiol 31: 150–153, 2002CrossRefPubMedGoogle Scholar
  11. 11.
    Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB, Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey Ann Intern Med 135: 344–351, 2001PubMedGoogle Scholar
  12. 12.
    Astin JA, Marie A, Pelletier KR, Hansen E, Haskell WL, A review of the incorporation of complementary, alternative medicine by mainstream physicians Arch Intern Med 158: 2303–2310, 1998CrossRefPubMedGoogle Scholar
  13. 13.
    Ashikaga T, Bosompra K, O’Brien P, Nelson L, Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians Support Care Cancer 10: 542–548, 2002CrossRefPubMedGoogle Scholar
  14. 14.
    Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D, Alternative therapies used by women with breast cancer in four ethnic populationsJ Natl Cancer Inst 92: 42–47, 2000CrossRefPubMedGoogle Scholar
  15. 15.
    van der WF, Streuli RA, Use of alternative medicine by patients with cancer in a rural area of Switzerland Swiss Med Wkly 133: 233–240, 2003PubMedGoogle Scholar
  16. 16.
    Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dunser M, Richter R, Fleischhacker WW, Sperner-Unterweger B, Use of alternative/complementary therapy in breast cancer patients – a psychological perspective Support Care Cancer 9: 267–274, 2001CrossRefPubMedGoogle Scholar
  17. 17.
    Cleary-Guida MB, Okvat HA, Oz MC, Ting W, A regional survey of health insurance coverage for complementary, alternative medicine: current status and future ramifications J Altern Complement Med 7: 269–273, 2001CrossRefPubMedGoogle Scholar
  18. 18.
    Cohen MH, Hrbek A, Davis RB, Schachter SC, Eisenberg DM, Emerging credentialing practices, malpractice liability policies, and guidelines governing complementary and alternative medical practices and dietary supplement recommendations: a descriptive study of 19 integrative health care centers in the United States Arch Intern Med 165: 289–295, 2005CrossRefPubMedGoogle Scholar
  19. 19.
    Pelletier KR, Astin JA, Haskell WL, Current trends in the integration and reimbursement of complementary and alternative medicine by managed care organizations (MCOs) and insurance providers: 1998 update and cohort analysis Am J Health Promot 14: 125–133, 1999PubMedGoogle Scholar
  20. 20.
    Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR, Knowledge of, attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway Eur J Cancer 40: 529–535, 2004CrossRefPubMedGoogle Scholar
  21. 21.
    Munstedt K, Entezami A, Wartenberg A, Kullmer U, The attitudes of physicians and oncologists towards unconventional cancer therapies (UCT)Eur J Cancer 36: 2090–2095, 2000CrossRefPubMedGoogle Scholar
  22. 22.
    Harris P, Rees R, The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature Complement Ther Med 8: 88–96, 2000CrossRefPubMedGoogle Scholar
  23. 23.
    Sparreboom A, Cox MC, Acharya MR, Figg WD, Herbal remedies in the United States: potential adverse interactions with anticancer agents J Clin Oncol 22: 2489–2503, 2004CrossRefPubMedGoogle Scholar
  24. 24.
    Kushi LH, Cunningham JE, Hebert JR, Lerman RH, Bandera EV, Teas J, The macrobiotic diet in cancer J Nutr 131: 3056S–3064S, 2001PubMedGoogle Scholar
  25. 25.
    Interviews and anecdotal reports: Posit Health News 13–15, 1998Google Scholar
  26. 26.
    Brown JK, Byers T, Doyle C, Coumeya KS, Demark-Wahnefried W, Kushi LH, McTieman A, Rock CL, Aziz N, Bloch AS, Eldridge B, Hamilton K, Katzin C, Koonce A, Main J, Mobley C, Morra ME, Pierce MS, Sawyer KA, Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices CA Cancer J Clin 53: 268–291, 2003PubMedCrossRefGoogle Scholar
  27. 27.
    Risberg T, Vickers A, Bremnes RM, Wist EA, Kaasa S, Cassileth BR, Does use of alternative medicine predict survival from cancer? Eur J Cancer 39: 372–377, 2003CrossRefPubMedGoogle Scholar
  28. 28.
    Green S, A critique of the rationale for cancer treatment with coffee enemas and dietJAMA 268: 3224–3227, 1992CrossRefPubMedGoogle Scholar
  29. 29.
    di Bella Study Group: Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. BMJ 318: 224–228, 1999Google Scholar
  30. 30.
    Zemskov SV, Prokopchuk OL, Susak YM, Ukrain treatment in a patient with breast carcinoma Case report Drugs Exp Clin Res 26: 253–254, 2000PubMedGoogle Scholar
  31. 31.
    Tagliaferri M, Cohen I, Tripathy D, Complementary and alternative medicine in early-stage breast cancer Semin Oncol 28: 121–134, 2001CrossRefPubMedGoogle Scholar
  32. 32.
    Johansson S, Gullbo J, Lindholm P, Ek B, Thunberg E, Samuelsson G, Larsson R, Bohlin L, Claeson P, Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells Cell Mol Life Sci 60: 165–175, 2003CrossRefPubMedGoogle Scholar
  33. 33.
    Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S, Cipak A, Sabolovic S, Konitzer M, Mang S, An overview on anticancer activities of the Viscum album extract Isorel Cancer Biother Radiopharm 16: 55–62, 2001CrossRefPubMedGoogle Scholar
  34. 34.
    Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J, Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort studyAnticancer Res 23: 5081–5087, 2003PubMedGoogle Scholar
  35. 35.
    Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS, Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients.Aprospective randomized controlled clinical trial Anticancer Res 24: 303–309, 2004PubMedGoogle Scholar
  36. 36.
    Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U, The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial Anticancer Res 24: 1293–1302, 2004PubMedGoogle Scholar
  37. 37.
    Dohmen W, Breier M, Mengs U, Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks. Anticancer Res 24: 1231–1237, 2004PubMedGoogle Scholar
  38. 38.
    Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H, Mistletoe in cancer – a systematic review on controlled clinical trials Eur J Med Res 8: 109–119, 2003PubMedGoogle Scholar
  39. 39.
    Mansky PJ, Mistletoe and cancer: controversies and perspectives Semin Oncol 29: 589–594, 2002CrossRefPubMedGoogle Scholar
  40. 40.
    Stauder H, Kreuser ED, Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research Onkologie 25: 374–380, 2002CrossRefPubMedGoogle Scholar
  41. 41.
    Gerhard I, Abel U, Loewe-Mesch A, Huppmann S, Kuehn JJ, Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer Forsch Komplementarmed Klass Naturheilkd 11: 150–157, 2004CrossRefPubMedGoogle Scholar
  42. 42.
    Kovacs E, The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients Phytother Res 16: 143–147, 2002CrossRefPubMedGoogle Scholar
  43. 43.
    Gabius S, Gabius HJ, [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks]Dtsch Med Wochenschr 127: 457–459, 2002PubMedGoogle Scholar
  44. 44.
    Ingram D, Sanders K, Kolybaba M, Lopez D, Case–control study of phyto-oestrogens and breast cancer Lancet 350: 990–994, 1997CrossRefPubMedGoogle Scholar
  45. 45.
    Messina M, Gardner C, Barnes S, Gaining insight into the health effects of soy but a long way still to go: commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease J Nutr 132: 547S−551S, 2002PubMedGoogle Scholar
  46. 46.
    Messina MJ: Legumes and soybeans: overview of their nutritional profiles and health effectsAm J Clin Nutr 70: 439S–450S, 1999PubMedGoogle Scholar
  47. 47.
    Chen J, Thompson LU, Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro Breast Cancer Res Treat 80: 163–170, 2003CrossRefPubMedGoogle Scholar
  48. 48.
    Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S, Soy, isoflavones, and breast cancer risk in Japan J Natl Cancer Inst 95: 906–913, 2003PubMedCrossRefGoogle Scholar
  49. 49.
    Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE, Phytoestrogens and breast cancer risk. Review of the epidemiological evidence Breast Cancer Res Treat 77: 171–183, 2003CrossRefPubMedGoogle Scholar
  50. 50.
    Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT, Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized, controlled trial Obstet Gynecol Surv 60: 41–43, 2005CrossRefGoogle Scholar
  51. 51.
    Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR, Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial JAMA 290: 207–214, 2003CrossRefPubMedGoogle Scholar
  52. 52.
    Nikander E, Kilkkinen A, Metsa-Heikkila M, Adlercreutz H, Pietinen P, Tiitinen A, Ylikorkala O, A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients Obstet Gynecol 101: 1213–1220, 2003CrossRefPubMedGoogle Scholar
  53. 53.
    Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, Wattie A, Prior JC, Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial J Clin Oncol 20: 1449–1455, 2002CrossRefPubMedGoogle Scholar
  54. 54.
    Fitzpatrick LA, Phytoestrogens – mechanism of action, effect on bone markers and bone mineral densityEndocrinol Metab Clin North Am 32(viii): 233–252, 2003CrossRefPubMedGoogle Scholar
  55. 55.
    Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG, Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF−7) cells implanted in athymic mice Cancer Res 62: 2474–2477, 2002PubMedGoogle Scholar
  56. 56.
    Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K, McKimmey C, Liu N, Thor A, Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention Cancer Res 65: 879–886, 2005PubMedGoogle Scholar
  57. 57.
    Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ, Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breastJ Clin Endocrinol Metab 84: 4017–4024, 1999CrossRefPubMedGoogle Scholar
  58. 58.
    Allred CD, Allred KF, Ju YH, Goeppinger TS, Doerge DR, Helferich WG: Soy processing influences growth of estrogen-dependent breast cancer tumors in mice. Carcinogenesis 25: 1649–1657, 2004Google Scholar
  59. 59.
    Murata M, Midorikawa K, Koh M, Umezawa K, Kawanishi S, Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs Biochemistry 43: 2569–2577, 2004CrossRefPubMedGoogle Scholar
  60. 60.
    Piersen CE, Phytoestrogens in botanical dietary supplements: implications for cancerIntegr Cancer Ther 2: 120–138, 2003CrossRefPubMedGoogle Scholar
  61. 61.
    Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K, Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB−435 human breast cancer cells Nutr Cancer 48: 95–105, 2004CrossRefPubMedGoogle Scholar
  62. 62.
    El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R, The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells Cancer Res 60: 4412–4418, 2000PubMedGoogle Scholar
  63. 63.
    Wang XF, Witting PK, Salvatore BA, Neuzil J, Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway Biochem Biophys Res Commun 326: 282–289, 2005CrossRefPubMedGoogle Scholar
  64. 64.
    Gerber B, Muller H, Reimer T, Krause A, Friese K, Nutrition and lifestyle factors on the risk of developing breast cancer Breast Cancer Res Treat 79: 265–276, 2003CrossRefPubMedGoogle Scholar
  65. 65.
    Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D’Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB, Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancerJ Natl Cancer Inst 91: 1847–1856, 1999CrossRefPubMedGoogle Scholar
  66. 66.
    Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD, Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer J Clin Oncol 21: 999–1006, 2003CrossRefPubMedGoogle Scholar
  67. 67.
    Lesperance ML, Olivotto IA, Forde N, Zhao Y, Speers C, Foster H, Tsao M, Macpherson N, Hoffer A, Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study Breast Cancer Res Treat 76: 137–143, 2002CrossRefPubMedGoogle Scholar
  68. 68.
    Saintot M, Mathieu-Daude H, Astre C, Grenier J, Simony-Lafontaine J, Gerber M, Oxidant-antioxidant status in relation to survival among breast cancer patients Int J Cancer 97: 574–579, 2002CrossRefPubMedGoogle Scholar
  69. 69.
    Willett WC, Stampfer MJ, What vitamins should I be taking, doctor?N Engl J Med 345: 1819–1824, 2001CrossRefPubMedGoogle Scholar
  70. 70.
    Food and Nutrition Board, Institute of Medicine: http://www. iom edu/board asp?id=3788 2004Google Scholar
  71. 71.
    Simopoulos AP, The traditional diet of Greece and cancerEur J Cancer Prev 13: 219–230, 2004CrossRefPubMedGoogle Scholar
  72. 72.
    Lopez-Saez JB, Senra-Varela A, Pousa-Estevez L, Selenium in breast cancer. Oncology 64: 227–231, 2003CrossRefPubMedGoogle Scholar
  73. 73.
    Vadgama JV, Wu Y, Shen D, Hsia S, Block J, Effect of selenium in combination with Adriamycin or Taxol on several different cancer cellsAnticancer Res 20: 1391–1414, 2000PubMedGoogle Scholar
  74. 74.
    Jiang C, Jiang W, Ip C, Ganther H, Lu J, Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake Mol Carcinog 26: 213–225, 1999CrossRefPubMedGoogle Scholar
  75. 75.
    Jiang C, Ganther H, Lu J, Monomethyl selenium – specific inhibition of MMP−2 and VEGF expression: implications for angiogenic switch regulationMol Carcinog 29: 236–250, 2000CrossRefPubMedGoogle Scholar
  76. 76.
    Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD, Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis Cancer Res 62: 4854–4859, 2002PubMedGoogle Scholar
  77. 77.
    Kopanski Z, Piekoszewski W, Habiniak J, Wojewoda T, Wojewoda A, Schlegel-Zawadzka M, Sibiga W, The clinical value of the determinations in the serum of zinc concentration in women with breast cancer Folia Histochem Cytobiol 39 Suppl2: 84–86, 2001PubMedGoogle Scholar
  78. 78.
    Woo W, Xu Z, Effect of dietary zinc intake on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats Biol Trace Elem Res 83: 169–179, 2001CrossRefPubMedGoogle Scholar
  79. 79.
    Schumacher K, [Effect of selenium on the side effect profile of adjuvant chemotherapy/radiotherapy in patients with breast carcinoma. Design for a clinical study] Med Klin (Munich) 94 Suppl3: 45–48, 1999Google Scholar
  80. 80.
    NCI. http://www.cancer.gov/. 2004 Google Scholar
  81. 81.
    Portakal O, Ozkaya O, Erden IM, Bozan B, Kosan M, Sayek I, Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients Clin Biochem 33: 279–284, 2000CrossRefPubMedGoogle Scholar
  82. 82.
    Lockwood K, Moesgaard S, Yamamoto T, Folkers K, Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases Biochem Biophys Res Commun 212: 172–177, 1995CrossRefPubMedGoogle Scholar
  83. 83.
    Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE, Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake Folia Microbiol (Praha) 43: 505–506, 1998Google Scholar
  84. 84.
    Beuth J, Ost B, Pakdaman A, Rethfeldt E, Bock PR, Hanisch J, Schneider B, Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients – results of an epidemiological multicentre retrolective cohort studyCancer Chemother Pharmacol 47Suppl: S45-S54, 2001CrossRefPubMedGoogle Scholar
  85. 85.
    Henderson JW, Donatelle RJ, Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancerAltern Ther Health Med 10: 52–57, 2004PubMedGoogle Scholar
  86. 86.
    Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, Kim SH, Lee YS, Kang KS, Modulations of the Bcl−2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF−7 human breast cancer cell J Agric Food Chem 52: 1715–1719, 2004CrossRefPubMedGoogle Scholar
  87. 87.
    Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D, Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 22: 3843–3852, 2002PubMedGoogle Scholar
  88. 88.
    Bocca C, Gabriel L, Bozzo F, Miglietta A, A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF−7 cells Chem Biol Interact 147: 79–86, 2004CrossRefPubMedGoogle Scholar
  89. 89.
    Norred CL, Finlayson CA, Hemorrhage after the preoperative use of complementary and alternative medicines AANA J 68: 217–220, 2000PubMedGoogle Scholar
  90. 90.
    Suzuki Y, Tsubono Y, Nakaya N, Suzuki Y, Koizumi Y, Tsuji I, Green tea and the risk of breast cancer: pooled analysis of two prospective studies in Japan Br J Cancer 90: 1361–1363, 2004CrossRefPubMedGoogle Scholar
  91. 91.
    Fujiki H, Two stages of cancer prevention with green teaJ Cancer Res Clin Oncol 125: 589–597, 1999CrossRefPubMedGoogle Scholar
  92. 92.
    Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ, A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma Cancer 97: 1442–1446, 2003CrossRefPubMedGoogle Scholar
  93. 93.
    Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA, Prevalence and treatment of menopausal symptoms among breast cancer survivorsJ Pain Symptom Manage 23: 501–509, 2002CrossRefPubMedGoogle Scholar
  94. 94.
    Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM, Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life A systematic review J Pain Symptom Manage 20: 374–387, 2000CrossRefPubMedGoogle Scholar
  95. 95.
    Alimi D, Rubino C, Pichard-Leandri E, Fermand-Brule S, Dubreuil-Lemaire ML, Hill C, Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial J Clin Oncol 21: 4120–4126, 2003CrossRefPubMedGoogle Scholar
  96. 96.
    Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, Shekelle PG, Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial JAMA 284: 2755–2761, 2000CrossRefPubMedGoogle Scholar
  97. 97.
    Bakke AC, Purtzer MZ, Newton P, The effect of hypnotic-guided imagery on psychological well-being and immune function in patients with prior breast cancer J Psychosom Res 53: 1131–1137, 2002CrossRefPubMedGoogle Scholar
  98. 98.
    Targ EF, Levine EG, The efficacy of a mind-body-spirit group for women with breast cancer: a randomized controlled trialGen Hosp Psychiatry 24: 238–248, 2002CrossRefPubMedGoogle Scholar
  99. 99.
    Hidderley M, Holt M, A pilot randomized trial assessing the effects of autogenic training in early stage cancer patients in relation to psychological status and immune system responses Eur J Oncol Nurs 8: 61–65, 2004CrossRefPubMedGoogle Scholar
  100. 100.
    Markman M: Safety issues in using complementary and alternative medicine. J Clin Oncol 20: 39S–41S, 2002CrossRefPubMedGoogle Scholar
  101. 101.
    Zhou S, Chan E, Pan SQ, Huang M, Lee EJ, Pharmacokinetic interactions of drugs with St John’s wort J Psychopharmacol 18: 262–276, 2004CrossRefPubMedGoogle Scholar
  102. 102.
    Izzo AA, Ernst E, Interactions between herbal medicines and prescribed drugs: a systematic review Drugs 61: 2163–2175, 2001CrossRefPubMedGoogle Scholar
  103. 103.
    Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ, Herbal bioactivation: the good, the bad and the ugly. Life Sci 74: 935–968, 2004CrossRefPubMedGoogle Scholar
  104. 104.
    Rockwell S, Liu Y, Higgins SA, Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh Breast Cancer Res Treat 90: 233–239, 2005CrossRefPubMedGoogle Scholar
  105. 105.
    Broxterman HJ, Lankelma J, Hoekman K, Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences Drug Resist Updat 6: 111–127, 2003CrossRefPubMedGoogle Scholar
  106. 106.
    Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ, Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John’s wort (Hypericum perforatum). Biochem Pharmacol 62: 1059–1070, 2001CrossRefPubMedGoogle Scholar
  107. 107.
    Mansky PJ, Straus SE, St.John’s Wort: more implications for cancer patients J Natl Cancer Inst 94: 1187–1188, 2002PubMedGoogle Scholar
  108. 108.
    Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M, Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death Breast Cancer Res Treat 90: 139–148, 2005CrossRefPubMedGoogle Scholar
  109. 109.
    Selvaraj V, Zakroczymski MA, Naaz A, Mukai M, Ju YH, Doerge DR, Katzenellenbogen JA, Helferich WG, Cooke PS, Estrogenicity of the isoflavone metabolite equal on reproductive and non-reproductive organs in mice Biol Reprod 71: 966–972, 2004CrossRefPubMedGoogle Scholar
  110. 110.
    Jenkins DJ, Kendall CW, Garsetti M, Rosenberg-Zand RS, Jackson CJ, Agarwal S, Rao AV, Diamandis EP, Parker T, Faulkner D, Vuksan V, Vidgen E, Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity – a controlled crossover trial Metabolism 49: 537–543, 2000CrossRefPubMedGoogle Scholar
  111. 111.
    Yap SP, Shen P, Butler MS, Gong Y, Loy CJ, Yong EL, New estrogenic prenylflavone from Epimedium brevicornum inhibits the growth of breast cancer cells Planta Med 71: 114–119, 2005CrossRefPubMedGoogle Scholar
  112. 112.
    Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ, Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial J Clin Oncol 18: 1068–1074, 2000PubMedGoogle Scholar
  113. 113.
    Zhang S, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K, Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB−435-FL-GFP breast cancer burden and metastasis in nude mice Breast Cancer Res Treat 87: 111–121, 2004CrossRefPubMedGoogle Scholar
  114. 114.
    Perumal SS, Shanthi P, Sachdanandam P, Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ(10): effects on lipid peroxidation and antioxidants in mitochondria Chem Biol Interact 152: 49–58, 2005CrossRefPubMedGoogle Scholar
  115. 115.
    Kissane DW, Love A, Hatton A, Bloch S, Smith G, Clarke DM, Miach P, Ikin J, Ranieri N, Snyder RD, Effect of cognitive-existential group therapy on survival in early-stage breast cancerJ Clin Oncol 22: 4255–4260, 2004CrossRefPubMedGoogle Scholar
  116. 116.
    AGO. http://www.ago-online.org. 2004. Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • B. Gerber
    • 1
    • 3
  • C. Scholz
    • 2
  • T. Reimer
    • 1
  • V. Briese
    • 1
  • W. Janni
    • 2
  1. 1.Department of Obstetrics and Gynecology University of RostockRostockGermany
  2. 2.I. Frauenklinik-InnenstadtLudwig-Maximilians-University MunichMunich Germany
  3. 3.Department of Obstetrics and GynecologyUniversity of RostockRostockGermany

Personalised recommendations